antiviral and associated therapy for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. anti-inflammatoty and immuno-therapy
vs. Immunostimulants drugs
vs. interferon
vs. Immunosuppressants drugs
vs. anti-interleukin-6
vs. tocilizumab
vs. antiviral and associated therapy
vs. azithromycin
vs. chloroquine and derivatives
vs. chloroquine
vs. hydroxychloroquine
vs. favipiravir
vs. hydroxychloroquine plus macrolides
vs. lopinavir/ritonavir
vs. remdesivir
vs. ribavirin
vs. umifenovir (arbidol)
vs. control
vs. placebo
vs. standard of care
vs. Vitamins
vs. vitamin C

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 0

table network network 2

display ongoing demontrated benefit only

popup

Zhao, 2021

favipiravir vs. standard of care

preventing respiratory virus transmission

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open